US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

26.14

0.0000

Volume:46

Turnover:1.21K

Market Cap:2.35M

PE:- -

High:26.14

Open:26.14

Low:26.14

Close:26.14

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:0.06

T/O Rate:0.05%

Dividend:0.45

Dividend Rate:1.72%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Tech Giant Pours Record €13 Billion into Nordic AI Hub

Evotec initiates clinical trial evaluating JST-018

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36

Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial

MediciNova to Participate in Two Investor Conferences in September

Press Release: Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend

Upstream Bio presents results from VALIANT trial at ERS Congress

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement

VOOLT launches deeptech strategy with co‑investment in biotech firm Pikralida

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Inventiva announces last patient visit in NATiV3 trial

PegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/NVIB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":26.13584,"timestamp":1789490688636,"preClose":26.13584,"halted":0,"volume":46,"delay":0,"changeRate":0,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"09-15 14:18:10 EDT","open":26.13584,"high":26.13584,"low":26.13584,"amount":1212.2462799999998,"amplitude":0,"askPrice":26.24,"askSize":100,"bidPrice":26.18,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":26.13584,"nav":27.319,"aum":2458779,"dividendRate":0.017245,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":26.415,"preClose":26.3635,"latestTime":"19:18 EDT","volume":62,"amount":1636.581,"timestamp":1789427917315,"change":0.0515,"changeRate":0.001953,"amplitude":0},"volumeRatio":0.061038},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.061038,"shares":90001,"dividePrice":0.4507,"high":26.13584,"amplitude":0,"preClose":26.13584,"low":26.13584,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":26.13584,"eps":0,"divideRate":0.017245,"volume":46,"delay":0,"ttmEps":0,"open":26.13584,"prevYearClose":25,"prevWeekClose":27.3696,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.2254,"twentyDayClose":28.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666858794","title":"Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358477/24675/en/fate-therapeutics-announces-encore-clinical-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-at-the-ccr-west-2026-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","CCR","BK4077","GDOC","HYLG","BMED","MEDX","NVIB","BK4139","SLE","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587949","title":"Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587949","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587949?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358458/0/en/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","LABU","GDOC","IDNA","BK4585","MEDX","NVIB","ARB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558799","title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358479/0/en/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-drug-candidate-sat-3247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DBB","INN","SAT","NVIB","BMED","HYLG","GDOC","BK4181","IDNA","BK4218","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155106466","title":"Tech Giant Pours Record €13 Billion into Nordic AI Hub","url":"https://stock-news.laohu8.com/highlight/detail?id=1155106466","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155106466?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:25","pubTimestamp":1788945959,"startTime":"0","endTime":"0","summary":"Search engine behemoth Alphabet is making its largest-ever European commitment, funneling €13 billion (approximately $15.1 billion USD) into Finnish artificial intelligence infrastructure. This...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0312595415.SGD","AIQD","SG9999015978.USD","LU0130517989.USD","AMZD","LU2462591350.SGD","IE00BJTD4V19.USD","LU2602419157.SGD","XDAT","LU1804176565.USD","AVGU","LU1069347547.HKD","LU2065169927.USD","IE00BDRTCR15.USD","LU1066051498.USD","LU2023250330.USD","BK4533","IE00BWXC8680.SGD","LU1989764748.USD","LU0211326755.USD","LU1303367103.USD","SG9999015986.USD","USJW.SI","AMZG","LU0784385170.HKD","LU0964807845.USD","LU0203202063.USD","SGXZ80539844.SGD","LU0472753341.HKD","BK4534","LU0795875169.SGD","LU1923623000.USD","LU0048573561.USD","IE00BJJMRY28.SGD","LU0215105999.USD","BK4527","LU0648001328.SGD","LU2462157665.USD","OGIG","LU0124676726.USD","LU2362541273.HKD","LU1951200564.SGD","LU0868494617.USD","AZYY","LU2592432038.USD","IE0001KFT4U8.USD","LU2746668461.USD","AVGW","IE00B7SZLL34.SGD","LU2087621335.USD","LU0345774631.USD","LU2347655073.USD","VOX","SMYY","LU1917777945.USD","LU2471134952.CNY","LU0943347566.SGD","LU1880398554.USD","LU1989772840.SGD","LU2462591277.SGD","LU0965509283.SGD","LU2242650005.HKD","LU2168563687.JPY","LU0689626769.HKD","LU2265009873.SGD","IE00BYXW3230.USD","LU0640476718.USD","AXTU","AIPI","LU1935042488.USD","BK4587","EPAI","LU2264538146.SGD","LU0942090050.USD","IE00BZ1G4Q59.USD","LU0345769631.USD","LU1935043452.HKD","LU0308772762.SGD","LU0029864427.USD","LU2089283258.USD","LU2097344431.USD","LU0106261372.USD","IE000SO60NU8.SGD","LU1674673428.USD","LU2458330169.SGD","LU1037948541.HKD","LU0211331839.USD","LU0079474960.USD","LU0354030511.USD","EFIV","XLC","LU0553294199.USD","BK4576","LU0965508806.USD","LU2999663052.SGD","SG9999014906.USD","RSPT","LU2756315664.SGD","LU0965509010.AUD","LU1868836914.USD","IE00BJTD4N35.SGD","SG9999000418.SGD","LU2746668974.SGD","LU0057025933.USD","IE0002270589.USD","QQQG","LU0072461881.USD","LU0889566641.SGD","LU0094547139.USD","IE00BJJMRX11.SGD","LU0496365809.HKD","LU2456880835.USD","LU0130518102.USD","SNPE","IE00BN29S564.USD","LU0077335932.USD","LU1868837136.USD","LU0096364046.USD","LU0289739343.SGD","BTHM","LU0128525929.USD","LU2244417387.USD","LU2237443549.SGD","LU2491050154.USD","IE00BLSP4239.USD","LU2102340556.USD","LU2361044949.HKD","LU0708994859.HKD","IE00B19Z9505.USD","TIME","IE00BMPRXN33.USD","LU2125154935.USD","LU0210533765.USD","LU1244550494.USD","LU0683600562.USD","LU0234572021.USD","LU0345768740.USD","LU0310799852.SGD","LU0868494708.USD","LU2404859741.USD","LU0980610538.SGD","SG9999015358.SGD","LTL","LU1066051225.USD","LU1551013425.SGD","SGXZ81514606.USD","LU1267930730.SGD","LU1839511570.USD","LU2461242641.AUD","LU2236285917.USD","SMCL","LU1935043536.SGD","AMZW","LU0203347892.USD","BK4566","LU1127390331.HKD","LU1059921491.USD","GOGL","LU0742534661.SGD","LU1221951046.USD","LU2237443978.SGD","LU2271345857.HKD","LU0203201768.USD","LU2191332357.HKD","LU2471134879.HKD","LU1699723380.USD","LU0545039389.USD","LU0557290698.USD","LU0672654240.SGD","SG9999014898.SGD","IVEP","LU0957808578.USD","LU2404859667.USD","LU0965509101.SGD","LU1244550221.USD","LU0210528500.USD","LU1496350502.SGD","DRAI","CNEQ","IE0004445015.USD","GPTY","LU0053666078.USD","AMZY","IE00BMPRXR70.SGD","LU1989772923.USD","LU2452424414.USD","GOOW","IE00BD6J9T35.USD","LU1894683264.USD","LU0511384066.AUD","WDAI","BK4592","GOU","LU2764263039.SGD","LU0788109477.HKD","GOOL","LU0061474705.USD","LU1267930490.SGD","GB00B4QBRK32.GBP","LU2087625088.SGD","LU0314104364.USD","LU0882574139.USD","LU0130102774.USD","LU1043141123.HKD","LU1003077747.HKD","LU0648000940.SGD","FRWD","LU2491049909.HKD","LU2750360641.GBP","WDCX","LU1791710582.SGD","LU1585245621.USD","LU1803068979.SGD","IE00B19Z3B42.SGD","LU2168564149.EUR","GGLS","IE00B19Z8W00.USD","IE00B3S45H60.SGD","LU1066051811.HKD","LU0096362180.USD","LU0289961442.SGD","LU2552382132.HKD","LU0719512351.SGD","SMCY","IE00BJLML261.HKD","LU0878866978.SGD","LU0070302665.USD","LU1934455863.HKD","LU0234570918.USD","DAT","LU2433249047.HKD","LU1934455194.USD","BK4514","LU0823421333.USD","LU0225283273.USD","HK0000304797.USD","LU0158827781.USD","LU2250418816.HKD","LU1066053197.SGD","LU2023250504.SGD","LU2360032135.SGD","LU2237438978.USD","THMZ","LU2065171402.SGD","LU1235294995.USD","LU1935043023.USD","TEK","LU2089284900.SGD","LU2125909593.SGD","LU1244550577.SGD","LU0198837287.USD","IE00BFSS8Q28.SGD","LU1923622614.USD","BK4561","IE00B5949003.HKD","LU0820561909.HKD","BK4548","IE00B775H168.HKD","LU1506573853.SGD","LU2357305700.SGD","LU1868836757.USD","LU0203345920.USD","LU1868837300.USD","LU0069063385.USD","LU0784385840.USD","LU1894683348.USD","SG9999018865.SGD","QBIG","LU0149725797.USD","LU0957791311.USD","BK4543","ORCX","CMAG","GOOG","LU2065171311.SGD","LU0994945656.USD","ILDR","LU1400636657.SGD","IE0004445239.USD","LU2361044865.SGD","LU0138981039.USD","LU0052756011.USD","LU0456855351.SGD","LU0823434740.USD","SG9999014559.SGD","ORAC","AMAA","IE000BZT7R73.USD","BK4532","SG9999017495.SGD","LU2211815571.USD","FXL","LU0786609619.USD","LU0128525689.USD","LU0859254822.USD","LU2098885051.SGD","SG9999014880.SGD","LU1935042991.SGD","HK0000532082.HKD","HK0000914660.USD","LU2637965513.SGD","GOOY","LU0174119429.USD","LU1202635105.USD","LU0256863811.USD","LU1074936037.SGD","SG9999002224.SGD","BAY","BK4077","LU1301847155.USD","BK4598","LU2764262908.HKD","LU2237443895.HKD","LU0289960550.SGD","LU0048584097.USD","AXTL","BK4602","LU2168564065.EUR","LU0251131958.USD","LU2362540622.SGD","SGXZ51526630.SGD","AIS","LU0444973449.USD","LU2023251221.USD","IE00BQXX3F31.USD","LU1868836591.USD","IE00B19Z3581.USD","LU2347655156.SGD","IE00B1XK9C88.USD","BK4585","LU0466842654.USD","LU1988902786.USD","LU0011850046.USD","LU2247934214.USD","LU1852331112.SGD","GXPC","IE0034235295.USD","LU0792757196.USD","LU0133085943.USD","LU1064131342.USD","BK4581","ORCU","BK4612","LU1880398471.USD","LU0080751232.USD","AXTQ","LU0444971666.USD","LU0211327993.USD","LU0320765059.SGD","XLKI","LU2237443465.HKD","LU0949170426.SGD","LU0082616367.USD","IE00BKDWB100.SGD","SG9999015945.SGD","IE00BMPRXQ63.HKD","LU2168564495.EUR","LU1691799644.USD","LU0354030438.USD","LU0310800965.SGD","LU0348723411.USD","SKYY","LU1720051108.HKD","LU1046421795.USD","LU2381873111.SGD","LU2764263203.CNY","AMZP","TTEQ","LU2326559502.SGD","LU1814569148.SGD","FDIF","LU1548497426.USD","IE0000B7K699.USD","LU1119994496.HKD","LU2286300806.USD","LU0061475181.USD","CRTC","LU0310800379.SGD","LU2213496289.HKD","LU2125154778.USD","ALAI","LU0353189680.USD","LU0823434583.USD","LU1366333091.USD","LU1201861249.SGD","LU0642271901.SGD","LU2111349929.HKD","SMCC","LU2860962120.EUR","LU0417517546.SGD","LU1670627923.USD","LU0097036916.USD","QXQ","LU1069344957.HKD","LU1914381329.SGD","LU1400636491.USD","AVL","IE00BYQQ9H92.USD","LU1121112475.USD","LU2471134523.USD","LU2133065610.SGD","LU1043141396.HKD","LU0323591593.USD","LU0157215616.USD","LU1035773651.USD","LU1674673691.USD","LU0320765489.SGD","LU0068578508.USD","LU0426412945.USD","LU2065170008.USD","LU0949170772.SGD","WDCC","GGLL","LU0820561818.USD","LU0820562030.AUD","LU1145028129.USD","LU0985489474.SGD","LU1201861165.SGD","LU1718418525.SGD","AMZU","IE00BFXG0V08.USD","LU0175139822.USD","IE00BQXX3D17.EUR","LU0130103400.USD","LU2106854487.HKD","SG9999018857.SGD","LU1633808545.USD","LU2077746001.SGD","IE000MB6IJN5.SGD","LU1153585028.USD","SG9999002232.USD","LU2357627491.SGD","IE0034235303.USD","SMCZ","AVGC","QQJG","ORCS","LU0433182093.SGD","GB00B4LPDJ14.GBP","LU1435385759.SGD","LU0345769128.USD","LU0823421416.USD","LU2720916845.USD","LU2125909247.SGD","LU2092627202.USD","LU1035775433.USD","SG9999015341.SGD","IE00BFSS7M15.SGD","LU0345770308.USD","AMZZ","LU2896262040.SGD","LU0056508442.USD","LU0162691827.USD","SG9999001077.SGD","BK4525","LU1084165304.USD","LU0302445910.USD","LU1267930573.SGD","LU1551013342.USD","LU0912757837.SGD","LU1815336760.USD","LU0784384876.USD","LU0724617625.USD","IE00B4JS1V06.HKD","LU0353189763.USD","LU0976567544.SGD","LU0795875086.SGD","LU0187121727.USD","LU0170899867.USD","LU2430703095.HKD","LU2054465674.USD","NTAL","LU0661504455.SGD","AXTC","LU0889565833.HKD","LU1280957306.USD","LU1316542783.SGD","IE000M9KFDE8.USD","BK4579","USMD","IE00BN8TJ469.HKD","LU0289941410.SGD","MQQQ","LU0690374961.EUR","LU0154236417.USD","LU2168564222.USD","LU1732799900.SGD","LU2097344357.USD","BK4573","LU1489326972.SGD","LU2458330243.SGD","BK4554","DARP","LU0345768153.USD","LU2420271590.USD","LU1989764664.SGD","LU1935042215.USD","LU2491050071.SGD","LU2108987350.USD","LU0342679015.USD","LU0494093205.USD","SGXZ31699556.SGD","LU2275660780.HKD","LU0061474960.USD","IE00BQXX3C00.GBP","LU1323610961.USD","LU0689472784.USD","NVIB","LU1778281490.HKD","LU1951198990.SGD","LU2471134796.USD","SG9999015952.SGD","IE000WAW04H5.SGD","AIVC","HK0000819398.USD","HK0000914686.HKD","QMNV","LU0787776722.HKD","IE00BK4W5M84.HKD","AMZO","LU0208291251.USD","TRUC","LU1366192091.USD","SG9999014914.USD","LU0426417589.USD","BK4574","SMCX","LU0784383803.USD","BK4588","LU0143551892.USD","SG9999014567.USD","GOOP","IE000F7OJYX1.SGD","LU1144417596.USD","LU0726765562.USD","IE00BZ199S13.USD","LU2552382215.SGD","IE00BLSP4452.SGD","LU2430703178.SGD","IE00BK4W5L77.USD","LU1116320737.USD","LU1815333072.USD","IE00B7KXQ091.USD","IE00BSNM7G36.USD","LU1934455277.USD","LU0211328371.USD","LU1267930813.SGD","LU2028103732.USD","LU2242649171.HKD","LU0210536198.USD","LU2417539215.USD","LU2750360997.AUD","LU0006306889.USD","LU0265550946.USD","LU2552382058.USD","LU0690374615.EUR","LU0211326839.USD","LU1232071149.USD","AXTX","IE0005OL40V9.USD","IE00BFMHRM44.USD","LU0708995401.HKD","LU2237443382.USD","LU0251142724.SGD","LU2237443622.USD","AVGX","LU0109391861.USD","IE00BDCRKT87.USD","LU2487616109.SGD","LU0127658192.USD","LU2756315318.SGD","IE00BBT3K403.USD","LU2505996509.AUD","LU1037948897.HKD","LU0316494557.USD","LU2092937148.SGD","AVGG","LU2954938101.SGD","SPRX","CQTM","LU1267930227.SGD","LU2023250843.SGD","LU1629891620.HKD","LU1823568750.SGD","IE00BKVL7J92.USD","LU0256863902.USD","LU0109392836.USD","LU0861579265.USD","LU1642822529.SGD","SGOOGmain","LU0238689110.USD","METV","LU0107464264.USD","LU2063271972.USD","GTEK","IE00BHPRN162.USD","LU0267386448.USD","LU1974910355.USD","LU1645745479.HKD","SG9999014575.USD","LU1221951129.SGD","GOOX","LU1732800096.USD","LU1261432733.SGD","LU0070217475.USD","LU0395794307.EUR","LU1430594728.SGD","ORCZ","LU0276348264.USD","LU1496350171.SGD","IE0004091025.USD","IE00BKPKM429.USD","TEKY","QNXT","BK4507","LU0314106906.USD","INVN","TTXU","LU0158827948.USD","BK4503","LU2430703251.USD","LU0345770993.USD","LU0985320562.USD","LU2360106780.USD","LU1670756490.USD","LU1803068623.USD","SG9999014542.SGD","LU2097829019.USD","LU0072462426.USD","BK4538","GOOGL","IE0034235188.USD","IE00B775SV38.USD","XQQI","AGIQ","LU0265550359.USD","LU2463028550.USD","LU1979441026.SGD","LU2361045086.USD","IE00B5TLWC47.USD","LU0345774391.USD","LU0528227936.USD","LU1571399168.USD","LU2543165471.USD","IE00B1BXHZ80.USD","LU0251132253.USD","LU1400636574.HKD","IE00B19Z8X17.USD","LU1116320901.HKD","LU0476273544.USD","FCOM","SGXZ44715902.SGD","LU1429558221.USD","IE0004086264.USD","LU0477156797.USD","HK0000304805.HKD","LU0738911758.USD","LU1196500208.SGD","SGXZ99366536.SGD","JGRO","LU1670628061.USD","BK4553","LU1032955483.USD","LU0477156953.USD","LU2362541513.USD","LU2403377893.USD","IE0009356076.USD","LU1791710400.SGD","BK4550","AVS","LU1720051017.SGD","LU2505996681.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589922","title":"Evotec initiates clinical trial evaluating JST-018","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589922?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:15","pubTimestamp":1788945324,"startTime":"0","endTime":"0","summary":"Evotec (EVO) announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","EVO","IDNA","GDOC","MEDX","BK4121","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","FHLC","IDNA","GDOC","AZNH","MEDX","SYNB","SURI","MNTL","TBXU","IEIH","BME","WDNA","GNMX","LLYX","PBE","HRTS","SBIO","NVIB","FBT","LFSC","PJP","MEDI","FTXH","MDTX","APXH","GNOM","IBRN","GSKH","BBP","XPH","PTH","RSPH","CURE","FXH","JDOC","JHMH","IBBQ","PINK","PSIL","IBBJ","IBB","MRNY","PBPH","BBH","HYLG","PSCH","BIB","CANC","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665730023","title":"Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665730023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665730023?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:11","pubTimestamp":1788873063,"startTime":"0","endTime":"0","summary":"An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma has repositioned itself as a precision oncology-led biotech, m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-sharpened-strategy-centers-on-precision-oncology-and-targeted-rare-disease-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-sharpened-strategy-centers-on-precision-oncology-and-targeted-rare-disease-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","CNCR","CANC","XBIX","BK4139","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","SBIO","GSKH","FHLC","IBBQ","BME","MDTX","RSPH","LLYX","CNCR","CURE","PBE","PJP","JDOC","IBBJ","BIB","CANC","LFSC","SYNB","FTXH","JHMH","PTH","IBRN","BBH","GPCR","TBXU","WDNA","PBPH","NVIB","HYLG","PSCH","SURI","PSIL","IBB","MEDI","BBP","FBT","PINK","FXH","MEDX","MNTL","HRTS","XPH","AZNH","GNMX","APXH","LENZ","GDOC","GNOM","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321700","title":"Ascletis Starts U.S. Phase I Trial of Oral Obesity Drug ASC36","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321700?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862087,"startTime":"0","endTime":"0","summary":"Ascletis Pharma, Inc. ( ($HK:1672) ) has issued an announcement. Ascletis Pharma Inc. has initiated a Phase I clinical trial in the U.S. for ASC36 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascletis-starts-u-s-phase-i-trial-of-oral-obesity-drug-asc36?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascletis-starts-u-s-phase-i-trial-of-oral-obesity-drug-asc36?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","NVIB","IDNA","MEDX","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665703321","title":"Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665703321","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665703321?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:05","pubTimestamp":1788861944,"startTime":"0","endTime":"0","summary":"Roivant announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-announces-positive-results-from-phase-2-phocus-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-announces-positive-results-from-phase-2-phocus-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","GDOC","MEDX","HYLG","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665601324","title":"MediciNova to Participate in Two Investor Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2665601324","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665601324?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"LA JOLLA, Calif., Sept.  08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchang","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357430/7767/en/medicinova-to-participate-in-two-investor-conferences-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4585","LU2133065610.SGD","BMED","LU0234570918.USD","LU0267386448.USD","LU0390134368.USD","LU2347655156.SGD","IDNA","LU1074936037.SGD","LU2028103732.USD","LU0106831901.USD","LU2111349929.HKD","BK4516","IE00BKVL7J92.USD","LU0795875169.SGD","LU0210528500.USD","LU1720051017.SGD","LU0053666078.USD","BK4588","BK4534","LU1732799900.SGD","LU0528227936.USD","LU1548497426.USD","LU1064131342.USD","LU1989772840.SGD","LU1791710582.SGD","MNOV","NVIB","KBWB","LU0098860793.USD","LU2264538146.SGD","LU0557290698.USD","LU1989772923.USD","LU2089283258.USD","LU1720051108.HKD","LU0971096721.USD","BK4127","LU0912757837.SGD","LU2089284900.SGD","GDOC","LU0006306889.USD","MEDX","LU1791710400.SGD","BK4504","IE00B3S45H60.SGD","LU2487616109.SGD","IAI","HYLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321351","title":"Press Release: Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321351?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc.  , a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three and six months ended June 30, 2026 and a cash dividend.Financial and Operational Highlights for the Second Quarter of 2026-- Strong Core Business Growth: Net operating revenue for the second quarter. rose to RMB1,448.2 million , representing a robust. year-over-year increase of 72.8%. Insurance-related income for the. quarter reached RMB1,333.2 million , up 80.5% from the. -- Improved Operating Performance: In the second quarter of 2026, operating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHAT","BK4509","NVIB","AGIX","QTOC","GDOC","BK4539","MEDX","VTHR","AIPO","ARTY","IDNA","WDH","HYLG","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326159","title":"Upstream Bio presents results from VALIANT trial at ERS Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326159?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:10","pubTimestamp":1788858619,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-presents-results-from-valiant-trial-at-ers-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-presents-results-from-valiant-trial-at-ers-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","UPB","NVIB","HYLG","GDOC","MEDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665157325","title":"Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665157325","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665157325?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:30","pubTimestamp":1788852600,"startTime":"0","endTime":"0","summary":"– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357341/0/en/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatment-of-severe-asthma-in-oral-presentation-at-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLQ","TSLG","TSL","TSLI","TEST","07766","TSLZ","TESC","GDOC","ELOL","MEDX","TLA","NVIB","TSLW","09366","TSLS","TSDD","HYLG","TSLO","TESL","CRSH","IDNA","09766","07366","TSII","TSYY","TSLP","TSLL","TSLT","TSLR","TSLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","PTH","GNMX","MEDI","FFOX","EKG","BK4535","GNOM","XLVX","BBP","IDNA","GDOC","TECB","NVIB","PINK","HELX","MRNX","LU0889565916.HKD","TBXU","LU0320765992.SGD","BK4196","LABU","GH","LU0109394709.USD","BK4551","FRTY","IEIH","IBB","SYNB","IYH","BK4588","RSPH","BMED","MRNY","LFSC","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325354","title":"Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325354","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325354?lang=en_us&edition=fundamental","pubTime":"2026-09-05 05:18","pubTimestamp":1788556694,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. ( ($PLRZ) ) has provided an update. Polyrizon Ltd., a NASDAQ-listed development-stage biotech based in Raanana, Israel, is building ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/polyrizon-raises-4-million-in-registered-direct-offering-and-private-placement-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/polyrizon-raises-4-million-in-registered-direct-offering-and-private-placement-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":[".IXIC","QQQE","SQQQ","03086","TECS","PSQ","QQQJ","NQmain","NVIB","QQQ","QQQA","QYLG","MNQmain","IYW","XBIX","ONEQ","QQQY","QID","TQQQ","NVIW.SI","GPIQ","JEPQ","QQQM","TQQY","FTEC","QDTE","QLD","NDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664808804","title":"VOOLT launches deeptech strategy with co‑investment in biotech firm Pikralida","url":"https://stock-news.laohu8.com/highlight/detail?id=2664808804","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664808804?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:21","pubTimestamp":1788445268,"startTime":"0","endTime":"0","summary":"VOOLT Spolka Akcyjna ( ($PL:VLT) ) just unveiled an update. VOOLT S.A. has made its first investment under a new deeptech‑focused strategy, committ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-launches-deeptech-strategy-with-coinvestment-in-biotech-firm-pikralida?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-launches-deeptech-strategy-with-coinvestment-in-biotech-firm-pikralida?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VLT","NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844613","title":"New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844613?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:50","pubTimestamp":1788385800,"startTime":"0","endTime":"0","summary":"Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) --  Revoluti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355564/0/en/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines-rasonque-daraxonrasib-in-metastatic-non-small-cell-lung-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU1854104046.USD","PTH","LU2487616109.SGD","LU1978683503.SGD","LU2357305700.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1854103824.USD","LU0348723411.USD","BBH","BK4588","IE00B2B36J28.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE00BZ199S13.USD","LU2298322129.HKD","IE0009354923.USD","NVIB","IE00BD6J9T35.USD","LU1861215975.USD","GDOC","IDNA","BMED","ON","ONG","LU0724618433.USD","BK4512","BK4605","LU1720051017.SGD","ONX","LU0109394709.USD","IE0009355771.USD","LU0124384867.USD","IE00BFTCPJ56.SGD","L","LU0053666078.USD","LU1861219969.SGD","BK4585","CANC","IE00B4R5TH58.HKD","LU1861220033.SGD","LU1983260115.SGD","IE00BFMHRM44.USD","RVMD","BK4139","BK4141","LU2360107325.USD","LU1548497426.USD","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841533","title":"Inventiva announces last patient visit in NATiV3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841533?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:35","pubTimestamp":1788381316,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","GDOC","MEDX","BK4139","IVA","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664890506","title":"PegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890506","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664890506?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:08","pubTimestamp":1788340086,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. Class H ( ($HK:2565) ) has shared an update. PegBio has entered a material transfer agreement with Korean biotech SN BioScience to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pegbio-partners-sn-bioscience-to-advance-long-acting-metabolic-peptide-candidates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pegbio-partners-sn-bioscience-to-advance-long-acting-metabolic-peptide-candidates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2242644610.SGD","BK4191","LU0128526141.USD","SN","XBIX","NVIB","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":181,"code":"91000000","status":"200"}]}}